SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection

被引：52
|
作者：
Bell, Robert M. [1 ]
Yellon, Derek M. [1 ]
机构：
[1] UCL, Hatter Cardiovasc Inst, London WC1E 6HX, England
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2018年 / 6卷 / 06期
关键词：
OUTCOMES; EMPAGLIFLOZIN;
D O I：
10.1016/S2213-8587(17)30314-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：435 / 437
页数：4
相关论文
共 50 条
  • [31] SGLT2 Inhibitors: A Comparison of Cardiovascular, Medical, and Cost Outcomes
    Schwab, Phil
    Bowe, Andy
    Tindal, Michael
    Meah, Yunus A.
    Poonawalla, Insiya
    DIABETES, 2020, 69
  • [32] Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
    Rabizadeh, Soghra
    Nakhjavani, Manouchehr
    Esteghamati, Alireza
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2019, 17 (02)
  • [33] The effect of SGLT2 inhibitors on cardiovascular events and renal function
    Imprialos, Konstantinos P.
    Stavropoulos, Konstantinos
    Doumas, Michael
    Karagiannis, Asterios
    Athyros, Vasilios G.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (11) : 1251 - 1261
  • [34] Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
    Abdullah Kaplan
    Emna Abidi
    Ahmed El-Yazbi
    Ali Eid
    George W. Booz
    Fouad A. Zouein
    Heart Failure Reviews, 2018, 23 : 419 - 437
  • [35] Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases
    Pan, Runfang
    He, Yuqing
    Melisandre, Wan
    Zhang, Yunyi
    Su, Wenyuan
    Feng, Jiaming
    Jia, Chengyao
    Li, Shaoling
    Liu, Baonian
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [36] Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
    Kaplan, Abdullah
    Abidi, Emna
    El-Yazbi, Ahmed
    Eid, Ali
    Booz, George W.
    Zouein, Fouad A.
    HEART FAILURE REVIEWS, 2018, 23 (03) : 419 - 437
  • [37] Can CMR Elucidate the Cardiovascular Benefit of SGLT2 Inhibitors?
    Nicholls, Stephen J.
    Nerlekar, Nitesh
    JACC-CARDIOVASCULAR IMAGING, 2021, 14 (06) : 1174 - 1176
  • [38] The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure
    Ji, Peng-juan
    Zhang, Zhuo-ya
    Yan, Qi
    Cao, Hui-li
    Zhao, Ya-jing
    Yang, Bing
    Li, Jin
    ESC HEART FAILURE, 2023, 10 (02): : 1314 - 1325
  • [39] SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients
    Vasquez-Rios, George
    Nadkarni, Girish N.
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2020, 13 : 281 - 296
  • [40] Cardiovascular protection by SGLT2 inhibitors-Do anti-inflammatory mechanisms play a role?
    Elrakaybi, Asmaa
    Laubner, Katharina
    Zhou, Qian
    Hug, Martin J.
    Seufert, Jochen
    MOLECULAR METABOLISM, 2022, 64
12345